Abdoli Asghar, Soleimanjahi Hoorieh, Jamali Abbas, Mehrbod Parvaneh, Gholami Shima, Kianmehr Zahra, Feizi Neda, Saleh Maryam, Bahrami Fariborz, Mokhtari-Azad Talat, Abdoli Mohsen, Kheiri Masoumeh Tavassoti
Departments of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran.
Biotechnol Lett. 2016 Jun;38(6):941-8. doi: 10.1007/s10529-016-2069-4. Epub 2016 Mar 5.
To evaluate MDCK and MDCK-SIAT1 cell lines for their ability to produce the yield of influenza virus in different Multiplicities of Infection.
Yields obtained for influenza virus H1N1 grown in MDCK-SIAT1 cell was almost the same as MDCK; however, H3N2 virus grown in MDCK-SIAT1 had lower viral titers in comparison with MDCK cells. The optimized MOIs to infect the cells on plates and microcarrier were selected 0.01 and 0.1 for H1N1 and 0.001 and 0.01 for H3N2, respectively.
MDCK-SIAT1 cells may be considered as an alternative mean to manufacture cell-based flu vaccine, especially for the human strains (H1N1), due to its antigenic stability and high titer of influenza virus production.
评估MDCK和MDCK - SIAT1细胞系在不同感染复数下产生流感病毒产量的能力。
在MDCK - SIAT1细胞中培养的甲型H1N1流感病毒产量与MDCK细胞几乎相同;然而,与MDCK细胞相比,在MDCK - SIAT1细胞中培养的H3N2病毒的病毒滴度较低。感染平板和微载体上细胞的最佳感染复数分别为甲型H1N1流感病毒0.01和0.1,H3N2流感病毒0.001和0.01。
由于MDCK - SIAT1细胞具有抗原稳定性和高滴度流感病毒生产能力,可被视为生产基于细胞的流感疫苗的替代方法,特别是对于人类毒株(H1N1)。